{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:55Z","timestamp":1792602955545,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2024ZZTS0522"],"award-info":[{"award-number":["2024ZZTS0522"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27599","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:21:07Z","timestamp":1709817667000},"page":"e27599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study"],"prefix":"10.1016","volume":"10","author":[{"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-9481","authenticated-orcid":false,"given":"Zhongyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27599_bib1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","article-title":"Breast cancer","volume":"365","author":"Veronesi","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27599_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41573-021-00018-6","article-title":"The breast cancer drug market","volume":"20","author":"Wilcock","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl 10","key":"10.1016\/j.heliyon.2024.e27599_bib3","doi-asserted-by":"crossref","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K inhibitors in advanced breast cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib4","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib5","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.heliyon.2024.e27599_bib6","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1073\/pnas.1205508109","article-title":"Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA)","volume":"109","author":"Burke","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e27599_bib7","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer","volume":"68","author":"Stemke-Hale","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27599_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e27599_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","article-title":"PI3K inhibitors in breast cancer therapy","volume":"21","author":"Ellis","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e27599_bib10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27599_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27599_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108196","article-title":"Divergent roles of PI3K isoforms in PTEN-deficient glioblastomas","volume":"32","author":"Xie","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e27599_bib14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e27599_bib16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27599_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib18","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","article-title":"Clinical and biomarker results from phase I\/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27599_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s43587-022-00349-y","article-title":"Dietary supplementation of clinically utilized PI3K p110alpha inhibitor extends the lifespan of male and female mice","volume":"3","author":"Hedges","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.heliyon.2024.e27599_bib21","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/bcp.15143","article-title":"Adverse events of alpelisib: a postmarketing study of the World Health Organization pharmacovigilance database","volume":"88","author":"Chen","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e27599_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2021.03.042","article-title":"Alpelisib in combination with everolimus +\/- exemestane in solid tumours: phase Ib randomised, open-label, multicentre study","volume":"151","author":"Curigliano","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e27599_bib24","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1002\/cncr.34928","article-title":"Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer","volume":"129","author":"Shen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e27599_bib25","article-title":"FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum (PROS)","author":"Singh","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27599_bib26","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a mutant-selective, allosteric PI3Kalpha inhibitor spares metabolic dysfunction and improves therapeutic response in PI3kalpha-mutant xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2024.e27599_bib27","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1093\/oncolo\/oyad092","article-title":"Beyond skin rash: alpelisib-induced anaphylactic reactions","volume":"28","author":"Schutte","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.heliyon.2024.e27599_bib28","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/1541-7786.MCR-23-0034","article-title":"CBF-beta mitigates PI3K-Alpha-Specific inhibitor killing through PIM1 in PIk3ca-mutant gastric cancer","volume":"21","author":"Stanland","year":"2023","journal-title":"Mol. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024036302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024036302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:27:06Z","timestamp":1782246426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024036302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024036302"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27599","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27599"}}